Literature DB >> 7502529

Zollinger-Ellison syndrome: past, present and future controversies.

R T Jensen1.   

Abstract

It is fitting that the Zollinger-Ellison syndrome (ZES) be included in the Lester Dragstedt Symposium because Dr. Dragstedt had a long-time interest in this disease, having been one of the five discussants of the original article and subsequently reporting with Dr. Oberhelman on nine cases. The approach to therapy of ZES has been controversial from the beginning, and a number of controversies remain. In this article, four different controversies are analyzed from the prospective of the past (Zollinger-Dragstedt era, 1955-1980), present and what may happen in the future in light of recent results. Specifically analyzed are: 1) the role of gastric surgery in the management; 2) whether gastrinoma removal without aggressive resection in patients with ZES without MEN-I is the preferred surgical therapy; 3) whether patients with MEN-I should undergo routine surgical exploration; and 4) whether most gastrinomas will be localized preoperatively. An analysis of recent advances suggests there may be marked changes in the future from our current and our past approaches.

Entities:  

Mesh:

Year:  1994        PMID: 7502529      PMCID: PMC2588927     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  84 in total

1.  THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES.

Authors:  E H ELLISON; S D WILSON
Journal:  Ann Surg       Date:  1964-09       Impact factor: 12.969

2.  Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study.

Authors:  B C Sheppard; J A Norton; J L Doppman; P N Maton; J D Gardner; R T Jensen
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

3.  Excisional therapy for ulcerogenic tumors of the duodenum: long-term results.

Authors:  H A Oberhelman
Journal:  Arch Surg       Date:  1972-04

4.  Selective venous sampling for gastrin to localize gastrinomas. A prospective assessment.

Authors:  J A Cherner; J L Doppman; J A Norton; D L Miller; A G Krudy; J P Raufman; M J Collen; P N Maton; J D Gardner; R T Jensen
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

5.  Role of selective angiography in the management of patients with Zollinger-Ellison syndrome.

Authors:  P N Maton; D L Miller; J L Doppman; M J Collen; J A Norton; R Vinayek; J I Slaff; S A Wank; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

6.  111In-octreotide scintigraphy in oncology.

Authors:  E P Krenning; D J Kwekkeboom; J C Reubi; P M van Hagen; C H van Eijck; H Y Oei; S W Lamberts
Journal:  Digestion       Date:  1993       Impact factor: 3.216

Review 7.  Zollinger-Ellison syndrome. Current concepts in diagnosis and management.

Authors:  M M Wolfe; R T Jensen
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

8.  Resection of gastrinomas.

Authors:  C W Deveney; K E Deveney; D Stark; A Moss; S Stein; L W Way
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

9.  Cimetidine in the treatment of Zollinger-Ellison syndrome.

Authors:  C W Deveney; S Stein; L W Way
Journal:  Am J Surg       Date:  1983-07       Impact factor: 2.565

10.  Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome).

Authors:  W Creutzfeldt; R Arnold; C Creutzfeldt; N S Track
Journal:  Hum Pathol       Date:  1975-01       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.